NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company, has announced the approval of inducement share options for three new non-executive hires. The Compensation Committee of NewAmsterdam's Board of Directors granted options covering 111,000 ordinary shares under the 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $15.91 per share, matching the closing market price on September 3, 2024. The vesting schedule spans four years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, contingent on continued employment. These grants are part of NewAmsterdam's strategy to attract talent in its mission to develop oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), un'azienda biotecnologica in fase avanzata, ha annunciato l'approvazione di opzioni su azioni induttive per tre nuove assunzioni non esecutive. Il Comitato Compensazione del Consiglio di Amministrazione di NewAmsterdam ha concesso opzioni su 111.000 azioni ordinarie nell'ambito del Piano Induttivo 2024, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni su azioni hanno un prezzo di esercizio di $15.91 per azione, corrispondente al prezzo di chiusura di mercato del 3 settembre 2024. Il piano di maturazione si estende su quattro anni, con il 25% che matura dopo un anno e il resto che matura in 36 rate mensili uguali, a condizione della continuazione dell'impiego. Queste concessioni fanno parte della strategia di NewAmsterdam per attrarre talenti nella sua missione di sviluppare medicinali orali non statinici per pazienti a rischio di malattie cardiovascolari con elevati livelli di LDL-C.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), una empresa biofarmacéutica en etapa avanzada, ha anunciado la aprobación de opciones de acciones inducidas para tres nuevas contrataciones no ejecutivas. El Comité de Compensación de la Junta Directiva de NewAmsterdam otorgó opciones sobre 111,000 acciones ordinarias bajo el Plan de Inducción 2024, en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las opciones de acciones tienen un precio de ejercicio de $15.91 por acción, que coincide con el precio de cierre del mercado el 3 de septiembre de 2024. El calendario de adquisición se extiende por cuatro años, con un 25% adquirido después de un año y el resto adquirido en 36 cuotas mensuales iguales, sujeto a la continuidad del empleo. Estas concesiones son parte de la estrategia de NewAmsterdam para atraer talento en su misión de desarrollar medicamentos orales no estatínicos para pacientes en riesgo de enfermedades cardiovasculares con LDL-C elevado.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS)는 후기 단계의 임상 생명공학 회사로서 세 명의 비임원 채용을 위한 유도 주식 옵션의 승인을 발표했습니다. NewAmsterdam의 이사회의 보상위원회는 Nasdaq 상장 규칙 5635(c)(4)를 준수하여 2024 유도 계획에 따라 111,000주의 보통주에 대한 옵션을 부여했습니다.
주식 옵션의 행사가는 $15.91로, 2024년 9월 3일의 시장 마감가와 일치합니다. 행사 일정은 4년에 걸쳐 진행되며, 1년 후 25%가 부여되고 나머지는 고용 지속 조건에 따라 36개월의 동일한 월 할부로 부여됩니다. 이 부여는 심혈관 질환에 대한 위험이 있는 환자를 위해 구강 비스타틴 약물을 개발하는 사명에 인재를 끌어들이기 위한 NewAmsterdam의 전략의 일환입니다.
La NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), une entreprise biopharmaceutique en phase clinique avancée, a annoncé l'approbation d'options d'actions incitatives pour trois nouvelles recrues non exécutives. Le Comité de Rémunération du Conseil d'Administration de NewAmsterdam a accordé des options portant sur 111 000 actions ordinaires dans le cadre du Plan d'Induction 2024, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Les options sur actions ont un prix d'exercice de 15,91 $ par action, correspondant au prix de clôture du marché du 3 septembre 2024. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % devenant acquis après un an et le reste étant acquis en 36 versements mensuels égaux, sous réserve de la continuation de l'emploi. Ces attributions font partie de la stratégie de NewAmsterdam pour attirer des talents dans sa mission de développer des médicaments oraux non statines pour les patients à risque de maladies cardiovasculaires avec un LDL-C élevé.
Die NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat die Genehmigung von Induktionsaktienoptionen für drei neue nicht geschäftsführende Einstellungen bekannt gegeben. Der Vergütungsausschuss des Boards von NewAmsterdam hat Optionen auf 111.000 Stammaktien im Rahmen des Induktionsplans 2024 gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
Die Aktienoptionen haben einen Ausübungspreis von $15.91 pro Aktie, der dem Schlusskurs vom 3. September 2024 entspricht. Der Vesting-Zeitraum erstreckt sich über vier Jahre, wobei 25% nach einem Jahr und der Rest in 36 gleichen Monatsraten, abhängig von einer fortgesetzten Anstellung, vorschriftsmäßig erworben werden. Diese Gewährungen sind Teil der Strategie von NewAmsterdam, Talente zu gewinnen, um orale, nicht-statinische Medikamente für Patienten mit erhöhtem LDL-C-Risiko für Herz-Kreislauf-Erkrankungen zu entwickeln.
- Attraction of new talent through share options, potentially enhancing the company's human capital
- Compliance with Nasdaq listing rules, maintaining good corporate governance
- Potential dilution of existing shareholders' equity due to the issuance of new share options
NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 111,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
FAQ
How many inducement share options did NewAmsterdam Pharma (NAMS) grant on September 3, 2024?
What is the exercise price of the share options granted by NewAmsterdam Pharma (NAMS) on September 3, 2024?
What is the vesting schedule for the share options granted by NewAmsterdam Pharma (NAMS) in September 2024?
